Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT

Anthony DUrzo,Dave Singh,James F. Donohue,Edward Kerwin,Anna Ribera,Eduard Molins,Ferran Chuecos,Diana Jarreta,Esther Garcia Gil

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT

2019

Anthony DUrzo
Dave Singh
James F. Donohue
Edward Kerwin
Anna Ribera
Eduard Molins
Ferran Chuecos
Diana Jarreta
Esther Garcia Gil

Background Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups.

Keywords:

Intensive care medicine
Augment
Exacerbation
Airflow
Internal medicine
Medicine
Gastroenterology
Formoterol
Placebo
Bronchodilator
COPD
Phases of clinical research
Morning
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations